These include inhibitors such as 2-deoxyglucose, ionidamine, and silibinin (Sborov et al., 2015), the latter of which was found to decrease SLC2A1, HK2, and LDHA (Shukla et al., 2015), which were observed in the present study to be increased in ESCC (Figure 3J). The gene discussed is HK2; the disease is esophageal squamous cell carcinoma.